Access cutting-edge heart disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access heart disease specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart disease treatment provided free
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Sponsor: Amgen
Check if you qualify for this heart disease clinical trial in Birmingham, AL
If you're searching for heart disease treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.